Rifabutin
2 NDCs across 2 manufacturers|2 Generic,0 Brand
Rifabutin is used to treat mycobacterium avium-intracellulare infection and pulmonary tuberculosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 23, 1992, and the first generic was approved Feb 24, 2014. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Rifabutin across 16,000 claims for 7,055 beneficiaries.
Rifabutin is available as 2 NDCs from 2 manufacturers (2 generic, 0 brand), with NADAC prices from $8.14 to $8.14 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
2G / 0B
Manufacturers
2
competing in market
Price Spread
$8.14 – $8.14
per EA
7d Activity
avg +0.4% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Mylan Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing RIFABUTIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RIFABUTIN 150 MG CAPSULE | $8.1363 per EA | +0.44% |
RIFABUTIN 150 MG CAPSULE | $8.1363 per EA | +0.44% |
Frequently Asked Questions
What is Rifabutin used to treat?
Rifabutin is used to treat mycobacterium avium-intracellulare infection and pulmonary tuberculosis, per the National Library of Medicine's MED-RT classification.
When did Rifabutin become available as a generic?
FDA approved the first generic Rifabutin (ANDA) on Feb 24, 2014. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rifabutin?
In 2024, Medicare Part D spent $7 million on Rifabutin across 16,000 claims for 7,055 beneficiaries.
How many Rifabutin products are on the market?
The Rifabutin drug market contains 2 NDCs from 2 manufacturers — 2 generic and 0 brand products.
What is the price range for Rifabutin?
NADAC reference prices for Rifabutin range from $8.1363 to $8.1363 per EA.
Which manufacturers make Rifabutin?
2 manufacturers list Rifabutin in NADAC. Ranked by number of NDCs, the largest are Mylan Pharmaceuticals Inc. (1), ANI Pharmaceuticals, Inc. (1).
How has the price of Rifabutin changed recently?
Over the past 7 days, 2 Rifabutin NDCs rose and 0 fell, with a market-wide average change of +0.4%.